Serum alkylresorcinols as biomarkers of dietary gluten exposure in coeliac disease

Choung, Rok Seon; Murray, Joseph A.; Marietta, Eric; Dyke, Carol T. Van; Ross, Alastair B.

doi:10.1111/apt.13917

Cited by 11 publications

(8 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the use of serum alkylresorcinols as a biomarker for a gluten‐free diet remains to be validated in larger studies, several studies have shown its potential 7–9 . The findings in our sample that serum alkylresorcinols were lower after the gluten‐free intervention compared with the gluten‐containing intervention support this, and indicates good compliance to the interventions, which we consider as a strength.…”

Section: Discussionsupporting

confidence: 72%

“…Although the use of serum alkylresorcinols as a biomarker for a gluten-free diet remains to be validated in larger studies, several studies have shown its potential. [7][8][9] The findings in our sample that serum alkylresorcinols were lower after the gluten-free intervention compared with the gluten-containing intervention support this, and indicates good compliance to the interventions, which we consider as a strength. Another strength of this study is the adequate blinding of the participants and investigators, and confounding factors were minimised by using the randomised crossover design, 23 and the strict in-and exclusion criteria.…”

Section: Step 4: Secondary Endpoint; Prediction Of Response To the Gl...supporting

confidence: 69%

“…After both interventions, serum samples were taken and serum alkylresorcinols were analysed using liquid chromatography/mass‐spectrometry (LC–MS) (Food and Nutrition Science, Chalmers Technical University, Gothenburg, Sweden) for assessment of compliance to both gluten‐free and gluten‐containing interventions. Alkylresorcinols are long‐chain phenolic lipids present in gluten‐containing grains, and both epidemiological and intervention studies have shown the potential of alkylresorcinols as a biomarker for both gluten intake and a gluten‐free diet 7–9 …”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Randomised controlled trial: effects of gluten‐free diet on symptoms and the gut microenvironment in irritable bowel syndrome

Algera

Magnusson

Öhman

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: A gluten-free diet reduces symptoms in some patients with irritable bowel syndrome (IBS) through unclear mechanisms.Aims: To assess the effects of gluten-free versus gluten-containing diet on symptoms and the gut microenvironment, and to identify predictors of response to the glutenfree diet in IBS Methods: Twenty patients with IBS and 18 healthy controls (HC) followed a glutenfree diet during two 14-day intervention periods where they sprinkled either gluten (14 g/day) or rice flour powder over their meals. Primary outcomes included effects of the interventions on IBS symptoms (IBS-SSS) and bowel habits. Secondary outcomes included effects of gluten-free diet on faecal microbiota and metabolite profile.Results: IBS symptoms improved during the gluten-free (p = 0.02), but not the glutencontaining period, with no difference between the interventions. IBS patients reported fewer loose stools during the gluten-free intervention (p = 0.01). Patients with IBS and HC presented distinct metabolite profiles based on the effects of the gluten-free diet (p < 0.001). True responders (reduced IBS-SSS by ≥50 solely after gluten-free period) and non-responders were discriminated based on the effects of the gluten-free diet on the microbiota (p < 0.01) and metabolite profiles (p < 0.001).The response to the gluten-free diet could be predicted by the metabolite profile before the intervention (p < 0.001). Conclusions:A gluten-free diet may influence symptoms in a subset of patients with IBS, with a particular effect on bowel habits. A gluten-free diet seems to impact the gut microenvironment. Responsiveness to the gluten-free diet may be predicted by the metabolite profile. Clini caltr ials.gov: NCT03869359.

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Step 4: Secondary Endpoint; Prediction Of Response To the Gl...supporting

confidence: 69%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Randomised controlled trial: effects of gluten‐free diet on symptoms and the gut microenvironment in irritable bowel syndrome

Algera

Magnusson

Öhman

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Serum AR concentrations, which can be used as a biomarker for gluten-containing diet in prior investigations, 22,23 were measured using the normal-phase liquid chromatographytandem mass spectrometry (LC-MS/MS), as described elsewhere 24 with some modifications for instrumentation. Briefly, 100 μL of serum was loaded on HybridSPE Plus phospholipid removal 96-well plates (Sigma-Aldrich, St Louis, MO, USA) and recovered with acetone.…”

Section: Measurement Of Alkylresorcinols (Ar)mentioning

confidence: 99%

Community-Based Study of Celiac Disease Autoimmunity Progression in Adults

et al. 2020

View full text Add to dashboard Cite

Background & Aims: Celiac disease can develop at any age, but outcomes of adults with positive results from serologic tests for tissue transglutaminase antibodies (tTGA) without endoscopic determination of celiac disease (called celiac autoimmunity) have not been thoroughly evaluated. We investigated the proportion of adults with celiac autoimmunity at a community medical center and their progression to celiac disease. Methods:We analyzed waste blood samples from a community clinic from 15,551 adults for tTGA and, if titers were above 2 U/mL, for endomysial antibody. The blood samples had been collected at 2 time points (median interval of 8.8 years), from 2006 through 2017. We collected data from the clinic on diagnoses of celiac disease based on duodenal biopsy analysis.Results: Of the serum samples collected at the first timepoint, 15,398 were negative for tTGA and were 153 positive for tTGA (>4 U/mL). Based on medical records, 6 subjects received a diagnosis of celiac disease, for a cumulative incidence of celiac disease diagnosis of 0.06% (95% CI, 0.01%-0.11%). Forty-nine subjects with a negative result from the first serologic test for tTGA

show abstract

“…Finally, adherence to diet in intervention studies is always a matter of worry. Even if our measures of serum alkylresorcinols 9 as a biomarker for adhering to a GFD remains to be validated, numerous studies, including a gluten challenge study in healthy volunteers, 10 have shown its potential.…”

mentioning

confidence: 99%

Editorial: gluten‐free but not pain‐free in IBS—authors' reply

Algera

Magnusson

Öhman

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Serum alkylresorcinols as biomarkers of dietary gluten exposure in coeliac disease

Abstract: Serum alkylresorcinol concentrations could be a useful marker for dietary gluten in coeliac disease.

Cited by 11 publications

References 51 publications

Randomised controlled trial: effects of gluten‐free diet on symptoms and the gut microenvironment in irritable bowel syndrome

Randomised controlled trial: effects of gluten‐free diet on symptoms and the gut microenvironment in irritable bowel syndrome

Community-Based Study of Celiac Disease Autoimmunity Progression in Adults

Editorial: gluten‐free but not pain‐free in IBS—authors' reply

Contact Info

Product

Resources

About